Investor Relations

Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.

Presentations

Financial Information

Press Releases

Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer’s Disease

Sep 14, 2020

Alzheimer’s Patients in Drug Groups Showed Statistically Significant Improvements in Biomarkers of Disease Compared to Placebo Group (P

Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ET

Sep 11, 2020

AUSTIN, Texas , Sept. 11, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Monday, September 14 th at 8:30 a.m.

View all